CN1248692C - 玻璃体结合蛋白受体拮抗剂在制备用于抑制粘连形成的药物中的用途 - Google Patents

玻璃体结合蛋白受体拮抗剂在制备用于抑制粘连形成的药物中的用途 Download PDF

Info

Publication number
CN1248692C
CN1248692C CNB028097874A CN02809787A CN1248692C CN 1248692 C CN1248692 C CN 1248692C CN B028097874 A CNB028097874 A CN B028097874A CN 02809787 A CN02809787 A CN 02809787A CN 1248692 C CN1248692 C CN 1248692C
Authority
CN
China
Prior art keywords
alkyl
adhesion
compound
adhesions
adhesion formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028097874A
Other languages
English (en)
Chinese (zh)
Other versions
CN1509170A (zh
Inventor
罗伯特·N·威利特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN1509170A publication Critical patent/CN1509170A/zh
Application granted granted Critical
Publication of CN1248692C publication Critical patent/CN1248692C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
CNB028097874A 2001-04-10 2002-04-10 玻璃体结合蛋白受体拮抗剂在制备用于抑制粘连形成的药物中的用途 Expired - Fee Related CN1248692C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28269301P 2001-04-10 2001-04-10
US60/282,693 2001-04-10

Publications (2)

Publication Number Publication Date
CN1509170A CN1509170A (zh) 2004-06-30
CN1248692C true CN1248692C (zh) 2006-04-05

Family

ID=23082703

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028097874A Expired - Fee Related CN1248692C (zh) 2001-04-10 2002-04-10 玻璃体结合蛋白受体拮抗剂在制备用于抑制粘连形成的药物中的用途

Country Status (26)

Country Link
EP (1) EP1385504B1 (cg-RX-API-DMAC7.html)
JP (1) JP4394882B2 (cg-RX-API-DMAC7.html)
KR (1) KR20030087069A (cg-RX-API-DMAC7.html)
CN (1) CN1248692C (cg-RX-API-DMAC7.html)
AP (1) AP2003002894A0 (cg-RX-API-DMAC7.html)
AT (1) ATE417612T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002305164B2 (cg-RX-API-DMAC7.html)
BG (1) BG108217A (cg-RX-API-DMAC7.html)
BR (1) BR0208789A (cg-RX-API-DMAC7.html)
CA (1) CA2443734A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20032767A3 (cg-RX-API-DMAC7.html)
DE (1) DE60230404D1 (cg-RX-API-DMAC7.html)
EA (1) EA006202B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP034799A (cg-RX-API-DMAC7.html)
ES (1) ES2319877T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0303725A3 (cg-RX-API-DMAC7.html)
IL (1) IL158272A0 (cg-RX-API-DMAC7.html)
MA (1) MA26159A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03009344A (cg-RX-API-DMAC7.html)
NO (1) NO20034513L (cg-RX-API-DMAC7.html)
NZ (1) NZ528577A (cg-RX-API-DMAC7.html)
OA (1) OA12505A (cg-RX-API-DMAC7.html)
PL (1) PL364526A1 (cg-RX-API-DMAC7.html)
UA (1) UA75395C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002083125A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200307621B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR052823A1 (es) * 2004-12-21 2007-04-04 Smithkline Beecham Corp Uso de un antagonista del receptor de vitronectina para l a preparacion de una formulacion farmaceutica util para inhibir el exceso de formacion de cicatrices en la piel de a un mamifero y dicha formulacion
RU2744540C1 (ru) * 2020-02-18 2021-03-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ профилактики спаечного процесса при операциях на брюшной полости в условиях паренхиматозного кровотечения в эксперименте

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Also Published As

Publication number Publication date
UA75395C2 (en) 2006-04-17
KR20030087069A (ko) 2003-11-12
EP1385504B1 (en) 2008-12-17
EA006202B1 (ru) 2005-10-27
BR0208789A (pt) 2004-03-09
ZA200307621B (en) 2004-04-21
HUP0303725A3 (en) 2009-08-28
ES2319877T3 (es) 2009-05-14
IL158272A0 (en) 2004-05-12
CN1509170A (zh) 2004-06-30
NZ528577A (en) 2005-01-28
MXPA03009344A (es) 2004-02-12
JP4394882B2 (ja) 2010-01-06
AP2003002894A0 (en) 2003-12-31
AU2002305164B2 (en) 2005-07-28
DE60230404D1 (cg-RX-API-DMAC7.html) 2009-01-29
CZ20032767A3 (cs) 2004-12-15
HUP0303725A2 (hu) 2004-03-01
EA200301109A1 (ru) 2004-02-26
OA12505A (en) 2006-05-29
BG108217A (bg) 2004-12-30
ECSP034799A (es) 2004-01-28
EP1385504A4 (en) 2007-03-14
CA2443734A1 (en) 2002-10-24
PL364526A1 (en) 2004-12-13
EP1385504A1 (en) 2004-02-04
NO20034513L (no) 2003-12-04
ATE417612T1 (de) 2009-01-15
MA26159A1 (fr) 2004-07-01
NO20034513D0 (no) 2003-10-08
WO2002083125A1 (en) 2002-10-24
JP2004525959A (ja) 2004-08-26

Similar Documents

Publication Publication Date Title
CN1152682C (zh) 用组胺受体拮抗剂组合物制备治疗上呼吸道变态反应的药物的用途
CN1221259C (zh) Cs-866、氯沙坦和坎迪沙坦用于制备治疗动脉硬化的药物
US20080234230A1 (en) Pharmaceutical Composition for Regulation of Pancreatic Juice Secretion Comprising a LPA Receptor Modulator
CN1338937A (zh) 3-羟基-3-甲基戊二酸单酰辅酶a还原酶抑制剂制造治疗糖尿病性神经病的药物的应用
JP2011518181A (ja) 炎症性疾患の治療のためのαアドレナリン作動性受容体アゴニスト
JP2014129402A (ja) 疼痛および/または炎症の治療のためのαアドレナリン作動性受容体アゴニスト
US20240075147A1 (en) Compositions Having Improved Bioavailability of Therapeutics
CN1192145A (zh) 最大限度地减少骨损失的方法
CN1859913A (zh) 改善肾功能损伤个体多尿症的方法
CN1248692C (zh) 玻璃体结合蛋白受体拮抗剂在制备用于抑制粘连形成的药物中的用途
CN1610548A (zh) 依贝沙坦在制备用来预防或治疗肺动脉高压的药物中的应用
TW202304424A (zh) 包含依維莫司和安森司群的組合
CN1216598C (zh) 药物用途
JP2009533413A (ja) 鎮痛剤およびビタミンを含む医薬組成物
CN100594933C (zh) 抗肥胖剂和健康食品
EP4406530A1 (en) Dosage form for intra-articular injection comprising colchicine for use in the treatment of a joint disease such as osteoarthritis
WO2003041717A1 (fr) Preparation pelliculaire persistante pour administration localisee contenant un derive de prostaglandine
JP5485704B2 (ja) 骨吸収と骨形成の不均衡を是正するための方法ならびにキット及び組成物
CN1893946A (zh) 吡唑衍生物在制备用于预防和治疗异常脂血症以及与异常脂血症和/或肥胖有关的疾病的药物中的应用
AU2002305164A1 (en) Method of inhibiting adhesion formation
US20040142918A1 (en) Method of inhibiting adhesion formation
JP2002541099A (ja) 免疫調節組成物およびその使用方法
CN1305379A (zh) 治疗方法
CN1655822A (zh) 含有acat抑制剂和胰岛素抵抗性改善剂的药用组合物
CN1319528C (zh) 用于预防心力衰竭的Na+-H+交换抑制剂卡立泊来德与ACE抑制剂雷米普利的联合制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060405